Merck
The Latest
-
Pfizer COVID-19 Pill Gets Emergency Use Authorization In South Korea
Countries are rushing to embrace Pfizer's pill as their first line of defense. 
Countries are rushing to embrace Pfizer's pill as their first line of defense. -
U.S. To Buy $5 Billion Worth Of Pfizer's Paxlovid COVID-19 Treatment
The White House is reportedly planning to purchase 10 million doses of Pfizer's Paxlovid COVID-19 treatment, at an estimated cost of $5 billion. The White House is reportedly planning to purchase 10 million doses of Pfizer's Paxlovid COVID-19 treatment, at an estimated cost of $5 billion. -
UK Approves COVID-19 Capsule By Merck And Ridgeback Bio In World First
The pill's approval comes as Britain struggles to contain infections. 
The pill's approval comes as Britain struggles to contain infections. -
Merck’s COVID-19 Pill Progress Triggers Asian Selloff In Vaccine Stocks
Merck's uplifting news of its oral drug sparked worries that demand for COVID-19 vaccines will drop in the upcoming months. 
Merck's uplifting news of its oral drug sparked worries that demand for COVID-19 vaccines will drop in the upcoming months. -
Warren Buffett Unveils Big Bets In U.S. Health Care
Buffett's bets on the U.S. health care sector could potentially pay off as the pandemic continues. 
Buffett's bets on the U.S. health care sector could potentially pay off as the pandemic continues. -
Merck Buys Drug Producer ArQule In $2.7 Billion Cash Deal
Merck will be purchasing cancer drug maker ArQule for $20 per share in an all-cash deal estimated to be worth around $2.7 billion. 
Merck will be purchasing cancer drug maker ArQule for $20 per share in an all-cash deal estimated to be worth around $2.7 billion.
